Genmab, which is developing antibody therapies and technologies for cancer and other diseases, filed on Tuesday with the SEC to raise up to $500 million in an initial public offering.
The Copenhagen, Denmark-based company was founded in 1998 and booked $440 million in sales for the 12 months ended March 31, 2019. It plans to list on the Nasdaq under the symbol GMAB. Genmab filed confidentially on February 5, 2019. BofA Merrill Lynch, Morgan Stanley and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
